Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook
10 Octobre 2024 - 7:00AM
UK Regulatory
Fagron reports outstanding third quarter 2024 performance with
12.1% revenue growth and reaffirms full-year outlook
Regulated information - inside information
Nazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 –
7:00 AM CET
Fagron reports outstanding third quarter 2024
performance with 12.1% revenue growth and reaffirms full-year
outlook
Fagron, the leading global player in pharmaceutical compounding
today publishes its quarterly results for the period ending 30
September 2024.
Key Highlights
- Continued topline momentum with
12.1% reported revenue growth (15.7% at CER) and 12.2% organic
growth at CER, delivering €214.5 million
- Strong organic growth across
all regions and segments, underscoring the strength of our
structural growth drivers
- Global operational excellence
initiatives remain a key contributor to revenue
development
- Three strategic acquisitions
signed across all regions and segments: Purifarma (B&E,
Brazil), Ritedose (CS, North America), EuroOTC (B&E,
Germany)
- Maintain FY 2024 revenue
outlook of €850 – €870 million and improvement in profitability
year-on-year
Rafael Padilla, CEO of Fagron:
Q3 has been another strong period for Fagron, highlighting
the strength of our business model and the consistent execution of
our strategy. Our focus on operational excellence and targeted
growth investments continues to deliver positive results across all
regions.
In EMEA, we have delivered an improving performance, driven
by our diversified business model, and Poland remains resilient as
we continue to advance on our strategic initiatives. Latin America
saw accelerated growth, especially in Brazil, benefitting from our
commercial and operational excellence efforts. North America
remains a key driver of growth, with Compounding Services and
B&E both delivering very strong results.
We are also pleased to announce the signing of three
acquisitions, which support our goal of securing market leadership
globally. With the acquisition of Purifarma in Brazil, and EuroOTC,
a raw material business in Germany, we are progressing towards our
objective of global leadership in B&E. Lastly, we acquired a
book of business from Ritedose in North America, which has a fully
compatible product portfolio with FSS. We remain committed to
exploring market opportunities globally, while maintaining our
disciplined M&A approach.
Looking to the end of the year, we are confident in our
outlook and reiterate our full-year 2024 and mid-term
guidance.”
Please open the link below for the full press release:
- Fagron reports outstanding third quarter 2024 performance with
12.1% revenue growth and reaffirms full-year outlook
Fagron NV (EU:FAGR)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Fagron NV (EU:FAGR)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024